Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis

Fig. 4

Functional biomarkers in patients undergoing immunomodulatory therapy after 17DD-YF vaccination. An in vitro 17DD-YF-specific lymphocyte proliferation assay was employed for antigen recall. Flow cytometric assay was carried out to identify functional T cell subsets, including cells producing TNF-α, IFN-γ, IL-10, and IL-5, as well as functional B cell subsets, including cells producing TNF-α, IL-10, and IL-5. The results are expressed as 17DD-YF Ag/CC index as described in the “Methods” section. Comparative analyses with the reference groups NV(day0) and PV(day30–45) were carried out using the mean value observed for each study group CONT(1–5 years), CONT(> 5–9 years), CONT(≥10 years), csDMARD(1–5 years), csDMARD(> 5–9 years), csDMARD(≥10 years), cs+bDMARD(1–5 years), cs+bDMARD(> 5–9 years), and cs+bDMARD(≥10 years) in comparison to the 95% CI of the reference groups, including NV(day0) (white rectangles) and PV(day30–45) (black rectangles). Significant differences were highlighted by letters “a” and “b” compared to NV(day0) or PV(day30–45), respectively

Back to article page